New drug could stop knee infections after replacement

NCT ID NCT07214311

Recruiting now Disease control Sponsor: Peptilogics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 05, 2026 · Updated 7 times

Summary

This study tests whether an investigational drug called PLG0206 can prevent infections from coming back after knee replacement surgery. About 240 adults who need a special cleaning surgery (DAIR) for an infected knee joint will receive either PLG0206 or a placebo during the procedure. Researchers will track them for one year to see if the drug reduces the need for further surgeries or other treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PLG0206 (an investigational drug used as an irrigation solution during surgery)
What this could lead to: If it works, this could provide a new way to prevent repeat infections after knee replacement surgery, reducing the need for additional surgeries.
What could go wrong: This is an early-to-mid-stage trial with only 240 participants, so results may not apply to everyone. The drug is still experimental, and its safety and effectiveness are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERIPROSTHETIC JOINT INFECTION FOLLOWING TOTAL KNEE ARTHROPLASTY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

periprosthetic joint infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTHETIC-JOINT INFECTION

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Clinical Trial Site
RECRUITING

Sarasota, Florida, 34239, United States
Clinical Trial Site
RECRUITING

Tamarac, Florida, 33321, United States
Clinical Trial Site
RECRUITING

Shreveport, Louisiana, 71103, United States
Clinical Trial Site
RECRUITING

Baltimore, Maryland, 21215, United States
Clinical Trial Site
RECRUITING

Boston, Massachusetts, 02120, United States
Clinical Trial Site
RECRUITING

New York, New York, 10032, United States
Clinical Trial Site
RECRUITING

Leland, North Carolina, 28451, United States
Clinical Trial Site
RECRUITING

Cincinnati, Ohio, 45267, United States
Clinical Trial Site
RECRUITING

Cleveland, Ohio, 44195, United States
Clinical Trial Site
RECRUITING

Columbus, Ohio, 43210, United States
Clinical Trial Site
RECRUITING

Pittsburgh, Pennsylvania, 15232, United States
Clinical Trial Site
RECRUITING

Dallas, Texas, 75390, United States
Clinical Trial Site
RECRUITING

Edinburg, Texas, 78539, United States
Clinical Trial Site
RECRUITING

Morgantown, West Virginia, 26506, United States
Clinical Trial Site
RECRUITING

Leeds, West Yorkshire, LS7 4SA, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.